341 related articles for article (PubMed ID: 20629191)
1. The 6-hydroxydopamine-induced nigrostriatal neurodegeneration produces microglia-like NG2 glial cells in the rat substantia nigra.
Kitamura Y; Inden M; Minamino H; Abe M; Takata K; Taniguchi T
Glia; 2010 Nov; 58(14):1686-700. PubMed ID: 20629191
[TBL] [Abstract][Full Text] [Related]
2. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.
Barcia C; Sánchez Bahillo A; Fernández-Villalba E; Bautista V; Poza Y Poza M; Fernández-Barreiro A; Hirsch EC; Herrero MT
Glia; 2004 May; 46(4):402-9. PubMed ID: 15095370
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
4. Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.
Maeda T; Nagata K; Yoshida Y
Neurosci Lett; 2008 Mar; 433(3):255-8. PubMed ID: 18255227
[TBL] [Abstract][Full Text] [Related]
5. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
6. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
7. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.
Voutilainen MH; Bäck S; Peränen J; Lindholm P; Raasmaja A; Männistö PT; Saarma M; Tuominen RK
Exp Neurol; 2011 Mar; 228(1):99-108. PubMed ID: 21185834
[TBL] [Abstract][Full Text] [Related]
8. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat.
Walsh S; Finn DP; Dowd E
Neuroscience; 2011 Feb; 175():251-61. PubMed ID: 21145947
[TBL] [Abstract][Full Text] [Related]
9. Curcumin protects nigrostriatal dopaminergic neurons and reduces glial activation in 6-hydroxydopamine hemiparkinsonian mice model.
Tripanichkul W; Jaroensuppaperch EO
Int J Neurosci; 2012 May; 122(5):263-70. PubMed ID: 22176529
[TBL] [Abstract][Full Text] [Related]
10. Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific sterological tools.
Gomide V; Bibancos T; Chadi G
Int J Neurosci; 2005 Apr; 115(4):557-82. PubMed ID: 15804725
[TBL] [Abstract][Full Text] [Related]
11. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
[TBL] [Abstract][Full Text] [Related]
12. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat.
Blandini F; Cova L; Armentero MT; Zennaro E; Levandis G; Bossolasco P; Calzarossa C; Mellone M; Giuseppe B; Deliliers GL; Polli E; Nappi G; Silani V
Cell Transplant; 2010; 19(2):203-17. PubMed ID: 19906332
[TBL] [Abstract][Full Text] [Related]
13. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
14. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Rosenblad C; Kirik D; Björklund A
Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
[TBL] [Abstract][Full Text] [Related]
15. Effect of unilateral lesion of the nigrostriatal dopamine pathway on survival and neurochemistry of parafascicular nucleus neurons in the rat--evaluation of time-course and LGR8 expression.
Sedaghat K; Finkelstein DI; Gundlach AL
Brain Res; 2009 May; 1271():83-94. PubMed ID: 19328193
[TBL] [Abstract][Full Text] [Related]
16. Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies.
Xu L; Sheng J; Tang Z; Wu X; Yu Y; Guo H; Shen Y; Zhou C; Paraoan L; Zhou J
Neurobiol Dis; 2005 Feb; 18(1):152-65. PubMed ID: 15649706
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic role of glial cells in Parkinson's disease.
Teismann P; Tieu K; Cohen O; Choi DK; Wu DC; Marks D; Vila M; Jackson-Lewis V; Przedborski S
Mov Disord; 2003 Feb; 18(2):121-9. PubMed ID: 12539204
[TBL] [Abstract][Full Text] [Related]
18. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.
Deumens R; Blokland A; Prickaerts J
Exp Neurol; 2002 Jun; 175(2):303-17. PubMed ID: 12061862
[TBL] [Abstract][Full Text] [Related]
19. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.
Marinova-Mutafchieva L; Sadeghian M; Broom L; Davis JB; Medhurst AD; Dexter DT
J Neurochem; 2009 Aug; 110(3):966-75. PubMed ID: 19549006
[TBL] [Abstract][Full Text] [Related]
20. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
